Sign in
OBIO Stock Price, Chart, Stats & News
Orchestra BioMed Holdings, Inc.
Save
245.51M
Market cap
–
Current P/E
–
Forward P/E
OBIO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.43% |
Operating margin | -154.73% |
Pretax margin | -157.40% |
Net margin | -157.40% |
Effective tax rate | – |
ROA | -45.88% |
ROE | -169.64% |
D/E | 0.51x |
Interest coverage ratio | -39.43x |
OBIO valuation
P/E | – |
P/S | 7.45x |
P/B | 2.58x |
P/CF | -3.34x |
P/FCF | -5.04x |
P/OCF | -3.34x |
PEG | -0.11x |
EV multiple | -4.90x |
About
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures.
Similar securities
Based on sector and market capitalization
Report issue